CytomX Therapeutics, Inc. (CTMX) Earnings Call Transcripts
CytomX Therapeutics, Inc.'s Latest Earnings Call - June 10, 2026
In Q2 2026, CytomX Therapeutics reported significant advancements in their clinical trials, focusing on their novel ADC, Viasat, and the Probody platform. While specific revenue and earnings figures were not disclosed in the transcript, the company emphasized the differentiated safety and efficacy profile of Viasat in late-line colorectal cancer (CRC), which could be a key driver for the stock. Management did not provide explicit guidance changes but highlighted upcoming pivotal studies and expansion into earlier treatment lines and other tumor types.
Reported metrics
| Metric | Value |
|---|---|
| Dose Optimization Enrollment | 20 patients per dose level (neutral) |
| Grade 3 Diarrhea Rate | 10% (positive) |
| CX801 Dose Levels | Third dose level (neutral) |
Guidance from management
Management plans to initiate the first pivotal study for Viasat in the first half of next year and is targeting earlier treatment lines and other tumor types for expansion.
What analysts pressed on
Analysts are focused on the broader application of Viasat beyond CRC and the potential for early-line treatment. They also inquired about the progress and differentiation of the CX801 program.
Main topics on the call
- Viasat Clinical Development — CytomX is advancing Viasat for late-line CRC, highlighting its 'remarkable antitumor activity' and 'low rates of hematologic toxicity.' The company is optimizing doses at 8.6 and 10 mg/kg and plans to begin pivotal studi...
- Safety Profile and Dose Optimization — Management reported 'unusually low rates of heme tox' for Viasat compared to competitors. They are employing prophylaxis and adjusted dosing to further enhance safety, aiming to maintain grade 3 diarrhea rates between 10...
- Expansion Strategy — CytomX plans to expand Viasat into earlier CRC treatment lines and other tumor types, leveraging its 'broad expression' of EpCAM. They aim for a pan-tumor label and are exploring combinations with bevacizumab and chemoth...
- CX801 Program — CX801, a masked interferon alpha, is in dose escalation trials for melanoma. Initial data shows 'powerful intratumoral modulation' and good tolerability, with combination trials with KEYTRUDA underway.
Read the full CytomX Therapeutics, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. (CTMX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 50 calls on record spanning February 27, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 50 CytomX Therapeutics, Inc. earnings call transcripts on record, spanning February 27, 2020 to August 6, 2026. Based on this history, CytomX Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CTMX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 50
- First call
- February 27, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly